| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 136, 3093-3099, Copyright © 1995 by Endocrine Society
ARTICLES |
DL Allen, MJ Low, RG Allen and N Ben-Jonathan
Department of Cell Biology, Neurobiology, and Anatomy, University of Cincinnati Medical School, Ohio 45267, USA.
Targeted tumorigenesis, using the POMC gene promoter ligated to the simian virus 40 large T antigen, generated transgenic mice with massive tumors of the intermediate lobe (IL) of the pituitary. Inoculation of nude mice with the IL tumor cells resulted in very large secondary tumors. As the IL from several species produces a potent PRL-releasing factor (PRF), it was of interest to determine whether IL tumors from these mice also contain PRF. The objectives were to 1) measure serum PRL levels in mice with IL tumors, 2) determine whether these tumors contain PRF and examine its chromatographic properties, and 3) analyze whether this PRF is related to POMC, its derivatives, or other PRL secretagogues. Serum PRL levels were 5- to 6-fold higher in transgenic than in control mice. Primary and secondary IL tumors were acid extracted and successively fractionated using Sephadex G-100 gel filtration and reverse phase and gel permeation HPLC. PRF activity was determined using short term incubation of tissue extracts or column fractions with GH3 cells. Crude tumor extracts exhibited a strong and dose-dependent PRF activity. Upon chromatography, the PRF activity from either primary or secondary tumors resolved into two classes of compounds: a big PRF with an estimated mol wt of 70-80 kilodaltons and two small, very hydrophobic peptides. The elution profiles of the three PRFs differed from those of beta-endorphin, alpha MSH, beta MSH, ACTH, TRH, oxytocin, angiotensin II, vasoactive intestinal polypeptide, or corticotropin-like intermediate peptide. In summary, we have identified an animal model with IL tumors that has hyperprolactinemia and overproduces PRF. Two classes of PRFs, big and small, were resolved which differ from POMC derivatives and known regulators of PRL release. These data suggest that PRF is produced by melanotrophs, but is not a product of the POMC gene. The IL tumors should provide an excellent source for the purification and structural elucidation of PRFs.
This article has been cited by other articles:
![]() |
C. Lin Chang, J. Roh, J.-I. Park, C. Klein, N. Cushman, R. V. Haberberger, and S. Y. T. Hsu Intermedin Functions as a Pituitary Paracrine Factor Regulating Prolactin Release Mol. Endocrinol., November 1, 2005; 19(11): 2824 - 2838. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hnasko, S. Khurana, N. Shackleford, R. Steinmetz, M. J. Low, and N. Ben-Jonathan Two Distinct Pituitary Cell Lines from Mouse Intermediate Lobe Tumors: A Cell that Produces Prolactin-Regulating Factor and a Melanotroph Endocrinology, December 1, 1997; 138(12): 5589 - 5596. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Steinmetz, N. G. Brown, D. L. Allen, R. M. Bigsby, and N. Ben-Jonathan The Environmental Estrogen Bisphenol A Stimulates Prolactin Release in Vitro and in Vivo Endocrinology, May 1, 1997; 138(5): 1780 - 1786. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |